RLMD smart money
Relmada Therapeutics, INC. (RLMD): 7 insider buys, 4 top funds holding it, 1 ETF change in the public filings.
Insider buys, 12 months$4.0M
Insider buys
| Filed | Who | Role | Amount | Price |
|---|---|---|---|---|
| 2026-09-11 | Shenouda Maged | Chief Financial Officer | $844k | $4.25 |
| 2026-09-11 | Traversa Sergio | Chief Executive Officer | $828k | $4.18 |
| 2025-12-16 | Traversa Sergio | Chief Executive Officer | $113k | $4.12 |
| 2025-11-06 | Shenouda Maged | Chief Financial Officer | $1.1M | $2.2 |
| 2025-11-06 | Traversa Sergio | Chief Executive Officer | $600k | $2.2 |
| 2025-11-06 | Ence Chuck | CAO and COO | $299k | $2.2 |
| 2025-11-06 | Kelly Paul Edward | Chief Operating Officer | $198k | $2.2 |
Top 100 funds holding it
| # | Fund | Change | Weight | Value |
|---|---|---|---|---|
| 2 | Venrock Adviser, LLC | ADD +9% | 1.36% | $28M |
| 24 | Orbimed Advisors LLC | TRIM -54% | 0.12% | $6M |
| 76 | Polar Capital Holdings PLC | 0.01% | $5M | |
| 86 | Adar1 Capital Management, LLC | ADD +22% | 0.10% | $2M |
ETF changes
| ETF | Change | Value | Report |
|---|---|---|---|
| State Street(R) Spdr(R) S&p(R) Pharmaceuticals ETF | BUY | +$4M | 2026-06-30 |